Oncternal Therapeutics Inc (NAS:ONCT)
$ 8.179 -0.456 (-5.28%) Market Cap: 24.21 Mil Enterprise Value: -9.73 Mil PE Ratio: 0 PB Ratio: 0.80 GF Score: 50/100

Q3 2019 Oncternal Therapeutics Inc Earnings Call Transcript

Nov 07, 2019 / 10:00PM GMT
Release Date Price: $115.6 (-3.99%)
Operator

Greetings, and welcome to the Oncternal Therapeutics third quarter earnings and business update call. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce Richard Vincent, CFO. Thank you. Please begin.

Richard G. Vincent
Oncternal Therapeutics, Inc. - CFO

Thank you, operator. Good afternoon, everyone, and thanks for joining us. I'd like to welcome you to our third quarter 2019 financial results and business update conference call. Joining me on the call this afternoon include our President and CEO, Dr. James Breitmeyer; and our Chief Medical Officer, Dr. Frank Hsu. Today's call will begin with a business update followed by a discussion of our third quarter 2019 results and a wrap-up with a Q&A.

Please note that today's quarterly press release is available on the Investor Relations section of Oncternal's website. Tomorrow, we plan to file our quarterly report on Form 10-Q for the quarter ended September 30, 2019. Our filings and a replay of this call will be available on the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot